Aptose Biosciences Inc. (APTO)

1.83
NASDAQ
Prev Close 1.83
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.57 / 4.55
Exchange NASDAQ
Shares Outstanding 41.50B
Market Cap 75.94M
Div & Yield N.A. (N.A)

Latest News

Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017

Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017

Conference Call and Webcast at 5pm EDT Today

OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting

OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting

CG'806 reveals broad and potent single agent activity, and enhanced activity when combined with Bcl-2 or BET inhibitors, against AML and CLL patient samples

Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting

Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting

Data elucidate unique ability of CG'806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents

Aptose Reports Results For The Third Quarter Ended September 30, 2017

Aptose Reports Results For The Third Quarter Ended September 30, 2017

Conference Call and Webcast at 5pm EST Today

Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC

Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC

Aptose Provides Corporate Update Highlights

Preclinical Data On Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented At AACR Hematologic Malignancies Meeting

Data support superiority of CG'806 relative to competitive agents against AML driven by diverse mutated forms of FLT3

OHSU And Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples At AACR Hematologic Malignancies Meeting

Data support superiority of CG'806 relative to select competitive agents

Aptose To Release First Quarter Ended March 31, 2017 Financial Results And Hold Conference Call On May 11, 2017

Provides Preliminary First Quarter 2017 Financial Information